Takeda Pharmaceutical Company Limited has reported positive topline results from two pivotal Phase 3 studies of its investigational drug zasocitinib (TAK-279), a once-daily oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The trials met all primary and secondary endpoints, with more than 50 percent of participants achieving near-complete skin clearance (PASI
Cosette Pharmaceuticals, Inc. has officially terminated its proposed AUD 7.40-per-share acquisition of Mayne Pharma Group Limited after the Australian government blocked the transaction. The decision was confirmed on December 9, 2025, and followed by Mayne Pharma’s own termination notice issued on December 11. The companies cited both the Treasurer of Australia’s ruling and the expiry
Alphyn Biologics has secured $25 million in a twice-oversubscribed Series B financing round to support its clinical pipeline for dermatologic conditions. The funding will enable the company to advance a global Phase 2b trial of its lead asset, Zabalafin Hydrogel, for atopic dermatitis, while also launching a second Phase 2 program for molluscum contagiosum virus.
Veradermics just completed pivotal trial enrollment for VDPHL01, its oral minoxidil for hair loss. Will it reshape dermatology? See what’s next.
Ascletis' acne drug denifanstat advances with NDA acceptance in China. Explore how FASN targeting could disrupt acne care and redefine systemic treatments.